IRIS
FAGGIANO, ANTONGIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.318
AS - Asia 1.599
EU - Europa 1.540
AF - Africa 73
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 6.540
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.241
SG - Singapore 614
IT - Italia 509
CN - Cina 497
HK - Hong Kong 434
NL - Olanda 190
SE - Svezia 162
FI - Finlandia 157
IE - Irlanda 142
DE - Germania 128
UA - Ucraina 104
CA - Canada 76
CI - Costa d'Avorio 72
GB - Regno Unito 44
RU - Federazione Russa 29
VN - Vietnam 25
FR - Francia 21
BE - Belgio 18
IN - India 15
CZ - Repubblica Ceca 8
LT - Lituania 8
ES - Italia 5
TR - Turchia 5
BR - Brasile 4
CH - Svizzera 3
EU - Europa 3
HU - Ungheria 3
HR - Croazia 2
IQ - Iraq 2
PL - Polonia 2
PT - Portogallo 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
BD - Bangladesh 1
IL - Israele 1
IR - Iran 1
JP - Giappone 1
KH - Cambogia 1
MD - Moldavia 1
MN - Mongolia 1
MX - Messico 1
OM - Oman 1
PE - Perù 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 6.540
Salva come PNG Salva come JPEG
Città #
Chandler 676
Singapore 488
Hong Kong 434
Santa Clara 256
Millbury 201
Ashburn 188
Amsterdam 184
Princeton 155
Nanjing 144
Jacksonville 113
Napoli 113
Naples 100
Beijing 97
Des Moines 74
Wilmington 74
Ottawa 65
Boston 52
Seattle 44
Helsinki 35
Nanchang 33
Hebei 32
Munich 29
Ann Arbor 27
Lawrence 26
Milan 25
Dong Ket 24
Shenyang 24
Houston 23
Rome 19
Tianjin 18
Woodbridge 17
Jiaxing 16
Norwalk 16
Washington 16
Boardman 14
Courcelles 14
Kunming 14
Kronberg 12
Dublin 11
Frankfurt am Main 11
Changsha 10
London 10
Pune 10
Toronto 10
Dearborn 9
Brno 8
Portici 8
Buffalo 7
Hangzhou 7
Los Angeles 7
Moscow 7
Philadelphia 7
New York 6
Shanghai 6
Falkenstein 5
Indiana 5
Lanzhou 5
Pagani 5
Paris 5
Portland 5
Zhengzhou 5
Arezzo 4
Bari 4
Brussels 4
Castel San Giorgio 4
Chongqing 4
Salerno 4
San Mateo 4
Andrano 3
Casavatore 3
Changchun 3
Dallas 3
Fairfield 3
Falls Church 3
Fuzhou 3
Jinan 3
Many 3
Orange 3
Palermo 3
Prineville 3
Redwood City 3
Shijiazhuang 3
Tappahannock 3
A Coruña 2
Albacete 2
Bicester 2
Bologna 2
Borgomanero 2
Cagliari 2
Carinola 2
Cerro al Lambro 2
Chicago 2
Genoa 2
Giugliano In Campania 2
Guangzhou 2
Lappeenranta 2
Leawood 2
Leverano 2
Marcianise 2
Messina 2
Totale 4.168
Salva come PNG Salva come JPEG
Nome #
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 78
Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. 69
MEN1 family with a novel frameshift mutation. 67
Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. 67
The evolving field of kinase inhibitors in thyroid cancer. 66
Hepatic arterial embolization in patients with neuroendocrine tumors. 65
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours 64
GLP-1: benefits beyond pancreas. 63
Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease 63
Endocrine dysfunction in patients with Fabry disease 61
Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity and Resilience 60
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR 57
Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules 55
Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma 51
Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours. 50
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission 50
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. 50
Emerging therapies in pheochromocytoma and paraganglioma: Immune checkpoint inhibitors in the starting blocks 50
A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. 49
Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors 49
Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study 49
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 49
CDKN1B V109G Polymorphism a New Prognostic Factor in Sporadic Medullary Thyroid Carcinoma. 48
Cushing's syndrome: aftermath of the cure. 48
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib 48
Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes 48
Diagnosis of Flier’s syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature 48
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 48
Limitations of Chromogranin A in clinical practice. 47
Insulin resistance and acne: a new risk factor for men? 47
Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer 47
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 47
Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features 46
Vitamin D and cancer. 46
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 46
Nutrition and neuroendocrine tumors: An update of the literature. 46
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy 45
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients 45
Thyroid function in Fabry disease before and after enzyme replacement therapy. 45
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 45
Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: An observational retrospective-prospective analysis from real life 45
Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1 45
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. 44
HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy 44
Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding? 43
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumors. 43
Rare diseases in clinical endocrinology: A taxonomic classification system 43
Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1 43
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms 43
Open issues on G3 neuroendocrine neoplasms: Back to the future 43
Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors 42
Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences 42
null 41
The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers 41
Chromogranin a as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame 41
Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. 41
Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors <2 cm 41
An incidental rectal neuroendocrine microcarcinoma ('micro-NEC') coexistent with a high grade adenoma 41
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions 41
Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors? 41
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study 40
Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature 40
Bone metastases in neuroendocrine neoplasms: From pathogenesis to clinical management 40
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 39
Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors 39
The roles of parathyroid hormone in bone remodeling. prospects for novel therapeutics 39
Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure 38
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 38
Diagnosis and differential diagnosis of MTC. 38
The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? 38
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 38
Complete remission of Nelson's syndrome after 1-year treatment with cabergoline 37
Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas 37
The management of neuroendocrine tumours: A nutritional viewpoint 37
The safety of available treatments options for neuroendocrine tumors 37
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature 37
Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms? 37
The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery 36
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. 36
STUDY OF HOMOCYSTEINE AND C677T POLYMORPHISM OF MTHFR IN YOUNG WOMEN WITH PCOS. 36
Targeted therapy with kinase inhibitors in aggressive endocrine tumors. 36
Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. 36
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib 36
Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) 36
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas. 36
Natural History of Localized and Locally Advanced Lung atypical Carcinoid after Complete Resection: A Joined French-ITALIAN Multicentric Retrospective Study 36
Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? 36
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies 36
Tumori neuroendocrini 35
In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinemic acromegalics. Correlation with somatostatin and dopamine D2 receptor scintigraphy. 34
Thyroid nodules and related symptoms are stably controlled two years afterradiofrequency thermal ablation. 34
BONE MASS AND BONE TURN-OVER AFTER BARIATRIC SURGERY IN MORBIDLY OBESE PATIENTS: RESULT OF A PILOT, OPEN, PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY. 34
Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database 33
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies (Oct, 10.1007/s40618-022-01905-4, 2022) 32
Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure 32
Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease 32
Hyperinsulinaemic hypoglycemia associated with ectopic Cushing syndromes due to a pancreatic endocrine tumor in a type 2 diabetes mellitus patient: clinical implications of a rare association. 32
Fibrous Variant of Hashimoto's Thyroiditis as a Diagnostic Pitfall in Thyroid Pathology 31
Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery 31
Animal models of medullary thyroid cancer: state of the art and view to the future 31
Totale 4.406
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.342
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.342
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020224 0 0 0 0 0 0 3 6 6 48 84 77
2020/2021363 10 21 53 26 25 76 25 3 40 16 34 34
2021/20221.063 13 1 32 5 22 97 3 33 158 69 234 396
2022/20231.563 191 137 38 141 192 165 44 131 214 208 82 20
2023/2024970 41 140 126 76 58 88 43 119 7 20 161 91
2024/20251.655 265 286 47 37 157 362 501 0 0 0 0 0
Totale 6.824